228 related articles for article (PubMed ID: 17638512)
1. Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance.
Zanger UM; Klein K; Saussele T; Blievernicht J; Hofmann MH; Schwab M
Pharmacogenomics; 2007 Jul; 8(7):743-59. PubMed ID: 17638512
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome P450 2B6: function, genetics, and clinical relevance.
Turpeinen M; Zanger UM
Drug Metabol Drug Interact; 2012; 27(4):185-97. PubMed ID: 23152403
[TBL] [Abstract][Full Text] [Related]
3. Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6.
Mo SL; Liu YH; Duan W; Wei MQ; Kanwar JR; Zhou SF
Curr Drug Metab; 2009 Sep; 10(7):730-53. PubMed ID: 19702527
[TBL] [Abstract][Full Text] [Related]
4. Pyrosequencing-based screening for genetic polymorphisms in cytochrome P450 2B6 of potential clinical relevance.
Rohrbacher M; Kirchhof A; Geisslinger G; Lötsch J
Pharmacogenomics; 2006 Oct; 7(7):995-1002. PubMed ID: 17054410
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes.
Hesse LM; He P; Krishnaswamy S; Hao Q; Hogan K; von Moltke LL; Greenblatt DJ; Court MH
Pharmacogenetics; 2004 Apr; 14(4):225-38. PubMed ID: 15083067
[TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients.
Nakajima M; Komagata S; Fujiki Y; Kanada Y; Ebi H; Itoh K; Mukai H; Yokoi T; Minami H
Pharmacogenet Genomics; 2007 Jun; 17(6):431-45. PubMed ID: 17502835
[TBL] [Abstract][Full Text] [Related]
7. CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme.
Wang H; Tompkins LM
Curr Drug Metab; 2008 Sep; 9(7):598-610. PubMed ID: 18781911
[TBL] [Abstract][Full Text] [Related]
8. [Cyclophosphamide and CYP2B6].
Torimoto Y; Kohgo Y
Gan To Kagaku Ryoho; 2008 Jul; 35(7):1090-3. PubMed ID: 18633247
[TBL] [Abstract][Full Text] [Related]
9. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism.
Burger D; van der Heiden I; la Porte C; van der Ende M; Groeneveld P; Richter C; Koopmans P; Kroon F; Sprenger H; Lindemans J; Schenk P; van Schaik R
Br J Clin Pharmacol; 2006 Feb; 61(2):148-54. PubMed ID: 16433869
[TBL] [Abstract][Full Text] [Related]
10. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children.
Saitoh A; Sarles E; Capparelli E; Aweeka F; Kovacs A; Burchett SK; Wiznia A; Nachman S; Fenton T; Spector SA
AIDS; 2007 Oct; 21(16):2191-9. PubMed ID: 18090046
[TBL] [Abstract][Full Text] [Related]
11. Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.
Bray J; Sludden J; Griffin MJ; Cole M; Verrill M; Jamieson D; Boddy AV
Br J Cancer; 2010 Mar; 102(6):1003-9. PubMed ID: 20179710
[TBL] [Abstract][Full Text] [Related]
12. Equine cytochrome P450 2B6--genomic identification, expression and functional characterization with ketamine.
Peters LM; Demmel S; Pusch G; Buters JT; Thormann W; Zielinski J; Leeb T; Mevissen M; Schmitz A
Toxicol Appl Pharmacol; 2013 Jan; 266(1):101-8. PubMed ID: 23142468
[TBL] [Abstract][Full Text] [Related]
13. CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction.
Levran O; Peles E; Hamon S; Randesi M; Adelson M; Kreek MJ
Addict Biol; 2013 Jul; 18(4):709-16. PubMed ID: 21790905
[TBL] [Abstract][Full Text] [Related]
14. Haplotype structure and allele frequencies of CYP2B6 in a Korean population.
Cho JY; Lim HS; Chung JY; Yu KS; Kim JR; Shin SG; Jang IJ
Drug Metab Dispos; 2004 Dec; 32(12):1341-4. PubMed ID: 15383491
[TBL] [Abstract][Full Text] [Related]
15. Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation.
Xie HJ; Yasar U; Lundgren S; Griskevicius L; Terelius Y; Hassan M; Rane A
Pharmacogenomics J; 2003; 3(1):53-61. PubMed ID: 12629583
[TBL] [Abstract][Full Text] [Related]
16. Q172H replacement overcomes effects on the metabolism of cyclophosphamide and efavirenz caused by CYP2B6 variant with Arg262.
Ariyoshi N; Ohara M; Kaneko M; Afuso S; Kumamoto T; Nakamura H; Ishii I; Ishikawa T; Kitada M
Drug Metab Dispos; 2011 Nov; 39(11):2045-8. PubMed ID: 21821736
[TBL] [Abstract][Full Text] [Related]
17. Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation.
Code EL; Crespi CL; Penman BW; Gonzalez FJ; Chang TK; Waxman DJ
Drug Metab Dispos; 1997 Aug; 25(8):985-93. PubMed ID: 9280407
[TBL] [Abstract][Full Text] [Related]
18. Genetic polymorphisms of cytochrome P450 2B6 gene in Han Chinese.
Guan S; Huang M; Chan E; Chen X; Duan W; Zhou SF
Eur J Pharm Sci; 2006 Sep; 29(1):14-21. PubMed ID: 16815693
[TBL] [Abstract][Full Text] [Related]
19. Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda.
Penzak SR; Kabuye G; Mugyenyi P; Mbamanya F; Natarajan V; Alfaro RM; Kityo C; Formentini E; Masur H
HIV Med; 2007 Mar; 8(2):86-91. PubMed ID: 17352764
[TBL] [Abstract][Full Text] [Related]
20. PXR polymorphisms interacted with CYP2B6 polymorphisms on methadone metabolites.
Tsai HJ; Wang SC; Tian JN; Chang TK; Ho IK; Hsiao CF; Chen CH; Tan HK; Lin L; Wu CS; Su LW; Huang CL; Yang YH; Liu ML; Lin KM; Liu YL
J Clin Psychopharmacol; 2013 Feb; 33(1):137-40. PubMed ID: 23288240
[No Abstract] [Full Text] [Related]
[Next] [New Search]
